Financials in USD. Standardized financial statements.
A compact view of how Sumitomo Pharma Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $480.63B | $398.83B | $314.56B | $555.54B | $560.03B | $515.95B | $482.73B | $459.27B | $466.84B | $411.64B |
| Revenue Growth? | +20.5% | +26.8% | -43.4% | -0.8% | +8.5% | +6.9% | +5.1% | -1.6% | +13.4% | 0.0% |
| Cost of Revenue? | $208.25B | $153.44B | $126.58B | $178.92B | $157.13B | $137.77B | $129.67B | $113.55B | $112.34B | $100.08B |
| Gross Profit? | $272.39B | $245.40B | $187.98B | $376.63B | $402.91B | $378.18B | $353.06B | $345.71B | $354.49B | $311.57B |
| Gross Margin? | +56.7% | +61.5% | +59.8% | +67.8% | +71.9% | +73.3% | +73.1% | +75.3% | +75.9% | +75.7% |
| Operating Expenses? | $219.01B | $216.59B | $542.17B | $453.60B | $342.67B | $306.95B | $269.82B | $287.83B | $266.32B | $258.81B |
| Operating Income? | $53.38B | $28.80B | -$354.19B | -$76.98B | $60.23B | $71.22B | $83.24B | $57.88B | $88.17B | $52.76B |
| EBITDA? | $75.42B | $56.67B | -$281.07B | -$3.50B | $124.36B | $103.11B | $104.17B | $79.23B | $95.61B | $56.18B |
| Income Before Tax | $106.40B | $17.61B | -$323.11B | -$47.92B | $82.96B | $77.85B | $83.95B | $65.05B | $84.87B | $47.22B |
| Income Tax Expense | -$6.91B | -$6.02B | -$8.19B | $48.79B | $42.36B | $41.02B | $48.03B | $16.42B | $31.42B | $18.23B |
| Net Income? | $113.31B | $23.63B | -$314.97B | -$74.51B | $56.41B | $56.22B | $40.75B | $48.63B | $53.45B | $28.99B |
| EPS? | $286.01 | $59.49 | $-792.79 | $-187.55 | $141.99 | $141.50 | $102.58 | $122.39 | $134.53 | $78.82 |
| Diluted EPS? | $286.01 | $59.49 | $-792.79 | $-187.55 | $141.99 | $141.50 | $102.58 | $122.39 | $134.53 | $78.82 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality